The company’s oncology liquid biopsy products offer enhanced detection and monitoring capabilities for late-stage cancer. Credit: Juan Ci/Shutterstock.

BillionToOne, a molecular diagnostics company, has secured $130m in an oversubscribed, upsized Series D funding round to expand and scale its prenatal screening and oncology diagnostics businesses.

The round was led by Premji Invest and saw substantial contributions from Neuberger Berman and existing investors including Baillie Gifford, Adam Street Partners, Hummingbird Ventures, Libertus Capital, Civilization Ventures and Fifty Years.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

BillionToOne’s QCTs technology has been pivotal in developing its diagnostic tests.

To date, more than 500,000 patients have benefitted from BillionToOne’s offerings, which have propelled the company to $125m in annual recurring revenue in approximately four years.

BillionToOne’s UNITY Fetal Risk Screen is said to be the first prenatal test of its kind, capable of assessing fetal risk for certain genetic conditions without partner samples.

See Also:

The company’s oncology liquid biopsy products, Northstar Select and Northstar Response, offer enhanced detection and monitoring capabilities for late-stage cancer patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Northstar Select has a detection limit up to five-times lower than competing assays, while Northstar Response offers ten times the precision of single nucleotide variant-based assays.

These products have been validated across various cancer types to accurately assess treatment responses.

With this latest funding round, total capital raised by BillionToOne to date nears $400m.

Akshay Rai, who led the Series D round, will join BillionToOne’s board of directors.

Rai said: “At Premji Invest, we aim to partner with exceptional teams, solving difficult problems while building enduring businesses.

“BillionToOne has made great progress in transforming the prenatal segment over the last few years, and after seeing the initial growth and potential of their liquid biopsy products, we are excited by the platform’s potential in expanding the diagnostics options available to clinicians in other specialties.”

In 2022, BillionToOne raised $125m through a Series C funding round to expand its commercial and clinical teams and boost laboratory capacity.